Methenamine Hippurate
Brand names: Methenamine Hippurate
At a glance
- Medicare prescriptions, 2024
- 705,758
- Medicare drug cost
- $46.7M
- Average cost per prescription
- $66.19
- Clinicians who prescribed it
- 18,538
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 26.1%
- Nurse Practitioners 22.5%
- Internal Medicine 14.5%
- Family Medicine 11.4%
- Physician Assistants 9.8%
- Urogynecology 4.9%
- Infectious Disease 3.1%
- Geriatric Medicine 2.5%
- OB-GYN (Obstetrics & Gynecology) 1.3%
- Nephrology (Kidney) 0.9%
- General Practice 0.6%
- Hospitalist 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 86% from 2019 to 2024.
Biggest change by state since 2019
- Missouri +166%
- Tennessee +139%
- North Carolina +130%
- Virginia +126%
- Texas +122%
- Louisiana (smallest change) +50%
- Nebraska (smallest change) +51%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ani Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | yellow capsule, 19 mm, scored to split in 2 | E50 |
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | white capsule, 19 mm, scored to split in 2 | E 71 |
Esjay Pharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | yellow capsule, 19 mm, scored to split in 2 | E50 |
Jubilant Cadista Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | white capsule, 19 mm, scored to split in 2 | L 59 |
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | white capsule, 19 mm, scored to split in 2 | E 71 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.